Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3

Molecular Cancer Therapeutics

Volumn 4, Issue 2, 2005, Pages 217-224

  Chen, Ting ^a   Pengetnze, Yolande ^a   Taylor, Christopher C ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CASPASE 3; CASPASE 9; CISPLATIN; CYTOCHROME C; HERBIMYCIN A; PACLITAXEL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASPASE 3; CASPASE 9; CASPASES; CISPLATIN; CYTOCHROMES C; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED;

EID: 14844333242     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cancer facts and figures. American Cancer Society. 2002. Available from: http://www.cancer.org/downloads/STT/CancerFacts&Figures2002TM.pdf.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer: a gynecologic oncology group trial (GOG 158). Proc Am Soc Clin Oncol 1999;18:356a.
4. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665-7.
5. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561-5.
6. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990;2:275-80.
7. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
8. NIH Consensus Conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. J Am Med Assoc 1995;273:491-7.
9. Park RC, Thigpen JT. Chemotherapy in advanced and recurrent cervical cancer. A review. Cancer 1993;71:1446-50.
10. Budde RJ, Ke S, Levin VA. Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 1994;14:171-5.
11. Wiener JR, Windham TC, Estrella VC, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003;88:73-9.
12. Luttrell DK, Luttrell LM, Parsons SJ. Augmented mitogenic response to FGF in murine fibroblasts that overexpress pp60 c-src. Mol Cell Biol 1988;8:497-501.
13. Kypta RM, Goldberg Y, Ulug ET, Courtneidge SA. Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell 1990;62:481-92.
14. Kremer NE, D'Arcangelo G, Thomas SM, De Marco M, Brugge JS, Halegoua S. Signal transduction by NGF and FGF in PC12 cells requires a sequence of src and ras actions. J Cell Biol 1991;115:809-19.
15. Pengetzne Y, Steed MS, Roby KR, Terranova PF, Taylor CC. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 2003; 309:377-83.
16. Ofir R, Seidman R, Rabinski T, et al. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ 2002;9:636-42.
17. Roby KF, Taylor CC, Cheng Y, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21:585-91.
18. Taylor CC, Terranova PF. Lipopolysaccharide inhibits rat ovarian thecal-interstitial cell steroid secretion in vitro. Endocrinology 1995;136:5527-32.
19. Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6:250-9.
20. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001;81:380-90.
21. Cannistra SA, Bast RC Jr, Barak JS, et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003;21 Suppl 1:129-32.
22. Griffiths GJ, Koh MY, Brunton VG, et al. Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem 2004;279:46113-21. Epub 2004 Aug 23.
23. Liu Z, Falola J, Zhu X, et al. Antiproliferative effects of Src inhibition on medullary thyroid cancer. J Clin Endocrinol Metab 2004; 89:3503-9.
24. Park SS, Eom YW, Kim EH, et al. Involvement of c-Src kinase in the regulation of TGF-β1-induced apoptosis. Oncogene 2004;23: 6272-81.
25. Windham TC, Parikh NU, Siwak DR, et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002;21:7797-807.
26. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998;1:949-57.
27. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68.
28. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 2000;403:98-103.
29. Yoneda T, Imaizumi K, Oono K, et al. Activation of caspase-12, an endoplasmic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. J Biol Chem 2001;276:1393-40. Epub 2001 Jan 29.
30. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001;61:1862-8.
31. Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 2003;13:399-404.
32. Zaffaroni N, Pennati M, Colella G, et al. Expression of the antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002;59:1406-12.
33. Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 2002;62: 924-31.
34. Richter BW, Duckett CS. The IAP proteins: caspase inhibitors and beyond. Sci STKE 2000;44:PE1 Review.